CHS-828

• Description:

  CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity[1].

• Product Name Alternative:

  GMX1778

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; NAMPT

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/GMX1778.html

• Purity:

  99.28

• Solubility:

  DMSO : ≥ 39 mg/mL

• Smiles:

  N#CN/C(NCCCCCCOC1=CC=C(C=C1)Cl)=N\C2=CC=NC=C2

• Molecular Formula:

  C19H22ClN5O

• Molecular Weight:

  371.86

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Watson M, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol. 2009 Nov;29 (21) :5872-88.|[2]Cerna D, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS) -mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1) -dependent manner. J Biol Chem. 2012 Jun 22;287 (26) :22408-17.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [200484-11-3]